Differences in prescriptions for systemic medications and nonsteroidal topicals among children with atopic dermatitis. Issue 2 (31st January 2023)

• Record Type: Journal Article
• Authors: Ahmed, Fahad; Takeshita, Junko; Wan, Joy
• Is Part Of: Pediatric dermatology. Volume 40:Issue 2(2023)
• Page Start: 315
• Page End: 319
• Publication Date: 2023-01-31
• Subjects: atopic dermatitis -- corticosteroid -- pediatrics -- systemic treatment -- topical calcineurin inhibitor; Pediatric dermatology -- Periodicals; Children -- Diseases -- Periodicals; 618.925
• DOI: 10.1111/pde.15263
• Languages: English
• ISSNs: 0736-8046

Abstract

Abstract: Nonsteroidal topicals and systemic therapies are often utilized for atopic dermatitis (AD) in children with inadequate response to topical corticosteroids. We sought to characterize patient factors associated with prescriptions for nonsteroidal topical (tacrolimus, pimecrolimus, crisaborole), systemic immunosuppressant (methotrexate, mycophenolate, cyclosporine, azathioprine), and systemic corticosteroid therapy among children with AD. In a cross‐sectional study of patients <18 years old with AD seen at a large children's hospital between 2009 and 2017, we found that nonsteroidal topical and systemic medication prescriptions were associated with older age of the patient, male sex, comorbid atopy, greater healthcare utilization, specialist care, and race/ethnicity. Compared to White patients, Black and Hispanic patients were less likely to be prescribed nonsteroidal topicals and non‐White patients were less likely to be prescribed systemic medications, suggesting that further examination of potential disparities in pediatric AD treatment is needed.